About Sevodyne2020-03-02T10:47:48+00:00


About Sevodyne

Welcome to sevodyne.co.uk

Sevodyne (buprenorphine) transdermal patches are indicated for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.1

Available as:

  • Transdermal patch 5 microgram/hr

  • Transdermal patch 10 microgram/hr

  • Transdermal patch 20 microgram/hr

Sevodyne transdermal patches are bioequivalent to Norspan®  (buprenorphine) (Mundipharma GmbH, Germany)/BuTrans® (buprenorphine) (Napp Pharmaceuticals Ltd, UK) buprenorphine transdermal patches.2

Sevodyne could offer significant cost savings to your practice and clinical commissioning group (CCG).3*

Buprenorphine 5 microgram/hr, 10 microgram/hr and 20 microgram/hr transdermal patches are in category C of the UK Drug Tariff.3

However, the NHS could make 55% savings on the cost of category C buprenorphine patches by prescribing Sevodyne by brand name.3*

Quite simply a wholesale switch of buprenorphine transdermal patches 5µg/hr, 10µg/hr and 20µg/hr prescriptions to Sevodyne could still save an average CCG £79,661 per year.4**

Sevodyne extends the existing Category C Cost-saving Prolonged-release Product Portfolio from Aspire Pharma.

In addition with Sevodyne you can get:

  • Pricing not dependent on competitor activity***

  • Price guaranteed***

*Based on 55% saving on the cost of Category C buprenorphine transdermal patches in the UK Drug Tariff.  ** Savings based on market data in reference 4. Savings calculated from 2018/2019 spend of 218 CCGs switching their generic and originator brand 5, 10 and 20mcg buprenorphine transdermal patch prescriptions to Sevodyne. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2024 PPRS review.
References: 1) Sevodyne SmPCs.  2) Data on file, 1010067149 v 4.0 October 2019.  3) February 2020 UK Drug Tariff.  4) epact data Sept 2018 – Sept 2019 (UK).


For further information please call: 01730 231148,
email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Sevodyne, please see the abbreviated prescribing information.

Revision reference – Sevodyne_7_28.02.2020

More products available
in this range:
Click to view their
individual websites